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1 Supplementary Methods 
Genotyping and Quality Control 
Initially, blood collected at baseline before the first randomization was used to isolate DNA for 
GWAS genotyping assays. However, the quality control step identified quality issues (DNA 
degradation) with about one half of the DNA samples. A second blood drawn was performed for 
available patients.  For those patients for whom a second blood drawn was not possible and 
whose DNA has quality issue, an Illumina FFPE restoration procedure was used for samples 
with quality problems. Of the samples, 1771 were from original blood, 1092 from redrawn blood 
samples and 459 from restored blood samples. DNA from 3304 patients was genotyped by the 
Center for Inherited Disease Research (CIDR) using the Illumina HumanOmniExpress-12v1 G 
FFPE array (Illumina, San Diego, CA), designed to human genome build 37. 3,252 genotyped 
subjects with covariate information were included in the analysis. 
Imputation and Fine Mapping 
1094 subjects from the “1000 genome” reference population were used as reference. The 
software BEAGLE v3.3.1 was used for 20-MB regions with 10-MB on each side of the SNP of 
interest. Imputed genotypes with a dosage R2 <0.3 were excluded from the analysis. The total 
number of genotyped and imputed SNPs for GWAS was 9,222,825 and that for the pathway-
based analysis was 325,934.  
Validation of Imputed Genotypes for the HMMR SNPs in LCLs 
We isolated DNA from seven LCLs that, based on imputation, possessed the variant genotype 
(five heterozygous, two homozygous variant) and from six LCLs homozygous wild-type 
genotype using the DNeasy Blood and Tissue Kit (QIAGEN, Germany). In order to verify the 
imputed genotypes, Sanger sequencing was undertaken in order to genotype these three SNPs in 
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HMMR. Primers were designed using the PrimerQuest application available from the IDT 
website (www.idtdna.com/Primerquest/Home/ Index). PCR was completed using 100 ng of 
DNA as template with primers flanking both rs299313 and rs29914. Forward and reverse PCR 
primers primers were 5'-GTAAGAAAGGCTGGAGCAGAA-3 and                        5’-
GGGAGCTGTACCCAGAAATG-3'. The primers 5'-GAGGTGGCTTACGCCTATAATC-3' 
and 5'-GAGACAGGATCTCACTCTGT-3' were used to sequence the PCR product containing 
the rs299313 and rs299314, respectively. Initial primers for PCR amplification of a region 
flanking rs299293 were 5'-TTCCATTGCCAGCTCCTTAG-3' and  5'-
GATCTTCTATCTCACTGGCTGTT -3. Sanger sequencing using the following primer, 5'-
ATGTTGGTCATGCTGGTCTC-3' were performed to verify the rs299293 genotype sequence. 
All samples were treated with the reagent Exo-SAP-IT® (Affymetrix, Santa Clara, CA) prior to 
sending samples for sequencing.  
 
2 Supplementary Figures 
 Supplementary Figure S1. Manhattan Plot of GWAS for Chemotherapy-induced Neutropenia 
in Breast Cancer Patients. A total of 3252 genotyped subjects with covariate information were 
included in the GWAS analysis. Cases were required to have Grade 3 or 4 toxicity according to 
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the National Cancer Institute (NCI)’s Common Terminology Criteria for Adverse Events v3.0. 
SNPs included in the GWAS analysis were genotyped by using the Illumina Human Omni 
Express Beadchip and were imputed based on the 1K Genomes data. SNP signals, with lowest p 
value of 2.4E-08, which mapped to the TNFSF13B on chromosome 13 were identified that were 
associated with chemotherapy-induced neutropenia. 
 
 
 
 
Supplementary Figure S2. The mRNA Levels of (A) TNFSF13B, (B) HMMR and (C) CCNG1 
in LCLs used in the Cytotoxicity Assay. The mRNA level was determined by the Affymetrix 
U133 2.0 Plus GeneChip expression array with specific probes as specified. The mRNA levels 
were grouped based on the genotype of HMMR SNPs (rs299293, rs299313, and rs299314), and 
compared between wild type (W/W) and heterozygous variant (W/V) plus homozygous variant 
(V/V, n = 2) genotypes by unpaired t test. Values are Mean ± S.E.M. A p value < 0.05 was 
considered statistically significant. ns = not significant. 
 
 
 
3 Supplementary Tables 
See attached Excel files for Supplementary Table S1 to S6. 
